Combination therapy for treatment of LKB1 deficient cancers
US11944615B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2021 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Sep 3, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of sensitizing LKB1/STK11 deficient cancers to immune therapy. A method for treatment for LKB1/STK11 deficient cancers is provided comprising administration of inhibitor or inhibitors of one or more of NAMPT, CD38, SHP2, CXCR1/2, HDAC4 and PARP in combination with immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.